Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications

Peter W. Andrews, Uri Ben-David, Nissim Benvenisty, Peter Coffey, Kevin Eggan, Barbara B. Knowles, Andras Nagy, Martin Pera, Benjamin Reubinoff, Peter J. Rugg-Gunn, Glyn N. Stacey

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.

Original languageEnglish
Number of pages4
JournalStem Cell Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 11 Jul 2017

Cite this

Andrews, P. W., Ben-David, U., Benvenisty, N., Coffey, P., Eggan, K., Knowles, B. B., ... Stacey, G. N. (2017). Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. Stem Cell Reports, 9(1). https://doi.org/10.1016/j.stemcr.2017.05.029
Andrews, Peter W. ; Ben-David, Uri ; Benvenisty, Nissim ; Coffey, Peter ; Eggan, Kevin ; Knowles, Barbara B. ; Nagy, Andras ; Pera, Martin ; Reubinoff, Benjamin ; Rugg-Gunn, Peter J. ; Stacey, Glyn N. / Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. In: Stem Cell Reports. 2017 ; Vol. 9, No. 1.
@article{2e28f6a15b264690bf03e1802b44b7d9,
title = "Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications",
abstract = "Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.",
author = "Andrews, {Peter W.} and Uri Ben-David and Nissim Benvenisty and Peter Coffey and Kevin Eggan and Knowles, {Barbara B.} and Andras Nagy and Martin Pera and Benjamin Reubinoff and Rugg-Gunn, {Peter J.} and Stacey, {Glyn N.}",
year = "2017",
month = "7",
day = "11",
doi = "10.1016/j.stemcr.2017.05.029",
language = "English",
volume = "9",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Elsevier",
number = "1",

}

Andrews, PW, Ben-David, U, Benvenisty, N, Coffey, P, Eggan, K, Knowles, BB, Nagy, A, Pera, M, Reubinoff, B, Rugg-Gunn, PJ & Stacey, GN 2017, 'Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications' Stem Cell Reports, vol. 9, no. 1. https://doi.org/10.1016/j.stemcr.2017.05.029

Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. / Andrews, Peter W.; Ben-David, Uri; Benvenisty, Nissim; Coffey, Peter; Eggan, Kevin; Knowles, Barbara B.; Nagy, Andras; Pera, Martin; Reubinoff, Benjamin; Rugg-Gunn, Peter J.; Stacey, Glyn N.

In: Stem Cell Reports, Vol. 9, No. 1, 11.07.2017.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications

AU - Andrews, Peter W.

AU - Ben-David, Uri

AU - Benvenisty, Nissim

AU - Coffey, Peter

AU - Eggan, Kevin

AU - Knowles, Barbara B.

AU - Nagy, Andras

AU - Pera, Martin

AU - Reubinoff, Benjamin

AU - Rugg-Gunn, Peter J.

AU - Stacey, Glyn N.

PY - 2017/7/11

Y1 - 2017/7/11

N2 - Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.

AB - Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85021993873&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2017.05.029

DO - 10.1016/j.stemcr.2017.05.029

M3 - Article

VL - 9

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 1

ER -